Clinical trial NCT04487080: A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Official title: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Carcinoma, Non-Small-Cell Lung
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2020-07-27
Enrollment: 1074
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).


Eligibility criteria: Inclusion Criteria:

* Participant must have newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation
* The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states \[US\]) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care
* Mandatory submission of unstained tissue from tumor (in a quantity sufficient to allow for central analysis of EGFR mutation status and blood (for circulating tumor deoxyribonucleic acid \[ctDNA\], digital droplet polymerase chain reaction \[ddPCR\], and pharmacogenomic analysis)
* Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level
* Participant must have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic biopsy and be acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy

Exclusion Criteria:

* Participant has received any prior systemic treatment at any time for locally advanced Stage III or metastatic Stage IV disease (adjuvant or neoadjuvant therapy for Stage I or II disease is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease)
* Participant has an active or past medical history of leptomeningeal disease
* Participant with untreated spinal cord compression. A participant that has been definitively treated with surgery or radiation and has a stable neurological status for at least 2 weeks prior to randomization is eligible provided they are off corticosteroid treatment or receiving low-dose corticosteroid treatment less than or equal to (\<=) 10 milligrams per day (mg/day) prednisone or equivalent
* Participant has an active or past medical history of interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis
* Participant has known allergy, hypersensitivity, or intolerance to the excipients used in formulation of amivantamab, lazertinib, or osimertinib, or any contraindication to the use of osimertinib
* Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study

Primary outcomes:
measure: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
timeFrame: From randomization to either disease progression or death whichever occurs first (up to 32.8 months)
Secondary outcomes:
Other outcomes:
Locations:
city: Goodyear
country: United States
facility: Arizona Oncology Associates, PC - HAL
state: Arizona
city: Yuma
country: United States
facility: Yuma Regional Medical Center
state: Arizona
city: Long Beach
country: United States
facility: City of Hope Long Beach Elm
state: California
city: Orange
country: United States
facility: University of California Irvine
state: California
city: Lone Tree
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Jacksonville
country: United States
facility: Cancer Specialists of North Florida
state: Florida
city: Athens
country: United States
facility: University Cancer And Blood Center LLC
state: Georgia
city: Metairie
country: United States
facility: East Jefferson General Hospital
state: Louisiana
city: Columbia
country: United States
facility: Maryland Oncology Hematology, PA
state: Maryland
city: Detroit
country: United States
facility: Henry Ford Hospital
state: Michigan
city: Edina
country: United States
facility: Minnesota Oncology Hematology P A
state: Minnesota
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Saint Louis
country: United States
facility: Washington University School Of Medicine
state: Missouri
city: East Brunswick
country: United States
facility: Astera Cancer Care
state: New Jersey
city: Eugene
country: United States
facility: Willamette Valley Cancer Institute and Research Center
state: Oregon
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
city: Austin
country: United States
facility: Texas Oncology P A
state: Texas
city: Houston
country: United States
facility: Oncology Consultants Texas
state: Texas
city: Fairfax
country: United States
facility: Virginia Cancer Specialists
state: Virginia
city: Buenos Aires
country: Argentina
facility: Centro Oncológico Korben
city: Buenos Aires
country: Argentina
facility: Instituto Alexander Fleming
city: Cordoba
country: Argentina
facility: Hospital Privado Centro Medico de Cordoba
city: La Rioja
country: Argentina
facility: Centro Oncologico Riojano Integral (Cori)
city: Viedma
country: Argentina
facility: Clínica Viedma
city: Bedford Park
country: Australia
facility: Flinders Medical Centre
city: Heidelberg
country: Australia
facility: Austin Hospital
city: Malvern
country: Australia
facility: Cabrini Medical Centre
city: Murdoch
country: Australia
facility: St John of God Hospital Murdoch
city: Nedlands
country: Australia
facility: Sir Charles Gairdner Hospital
city: Westmead
country: Australia
facility: Westmead Hospital
city: Wollongong
country: Australia
facility: Southern Medical Day Care Centre
city: Woolloongabba
country: Australia
facility: Princess Alexandra Hospital
city: Bruxelles
country: Belgium
facility: Cliniques Universitaires Saint Luc
city: Charleroi
country: Belgium
facility: Grand Hopital De Charleroi Site Les Viviers
city: Leuven
country: Belgium
facility: UZ Leuven
city: Ottignies
country: Belgium
facility: Clinique Saint Pierre
city: Roeselare
country: Belgium
facility: Algemeen Ziekenhuis Delta
city: Barretos
country: Brazil
facility: Fundacao Pio XII
city: Belo Horizonte
country: Brazil
facility: Cetus Oncologia
city: Florianopolis
country: Brazil
facility: Ynova Pesquisa Clinica
city: Ijui
country: Brazil
facility: Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
city: Natal
country: Brazil
facility: Liga Norte Riograndense Contra O Cancer
city: Pelotas
country: Brazil
facility: UPCO Unidade de Pesquisa Clinica em Oncologia
city: Porto Alegre
country: Brazil
facility: Irmandade Santa Casa de Misericordia de Porto Alegre
city: Porto Alegre
country: Brazil
facility: Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
city: Rio De Janeiro
country: Brazil
facility: Ministerio da Saude Instituto Nacional do Cancer
city: Rio de Janeiro
country: Brazil
facility: Oncoclinicas Rio de Janeiro S A
city: Rio de Janeiro
country: Brazil
facility: Instituto D Or de Pesquisa e Ensino IDOR
city: Sao Paulo
country: Brazil
facility: Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo
city: Sao Paulo
country: Brazil
facility: Fundacao Antonio Prudente A C Camargo Cancer Center
city: Sao Paulo
country: Brazil
facility: Núcleo de Pesquisa São Camilo
city: Sorocaba
country: Brazil
facility: IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
city: Vitoria
country: Brazil
facility: Hospital Evangélico de Cachoeiro de Itapemirim
city: Brampton
country: Canada
facility: William Osler Health System
state: Ontario
city: Hamilton
country: Canada
facility: Juravinski Cancer Centre
state: Ontario
city: Ottawa
country: Canada
facility: The Ottawa Hospital Cancer Centre
state: Ontario
city: Montreal
country: Canada
facility: McGill University Health Centre
state: Quebec
city: Beijing
country: China
facility: Beijing Friendship Hospital Capital Medical University
city: Beijing
country: China
facility: Beijing Cancer Hospital
city: Beijing
country: China
facility: Chinese PLA General Hospital
city: Beijing
country: China
facility: Beijing Chest hospital, Capital medical university
city: Changchun
country: China
facility: Jilin cancer hospital
city: Changsha
country: China
facility: Hunan Cancer hospital
city: Changzhou
country: China
facility: The First People's Hospital Of Changzhou
city: Chengdu
country: China
facility: Sichuan Cancer Hospital
city: Chengdu
country: China
facility: West China Hospital Sichuan University
city: ChongQing
country: China
facility: Southwest Hospital
city: Guang Zhou
country: China
facility: The First Affiliated Hospital Sun Yat sen University
city: Guangzhou
country: China
facility: Sun Yat-Sen Memorial Hospital Sun Yat-sen University
city: Hang Zhou
country: China
facility: Zhejiang Cancer Hospital
city: Hangzhou
country: China
facility: Second Affiliated Hospital, School of Medicine, Zhejiang University
city: Hangzhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University College of Medicine
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital Zhejiang University School of Medicine
city: Harbin
country: China
facility: Harbin medical university cancer hospital
city: Huizhou
country: China
facility: Huizhou Municipal Central Hospital
city: Linhai
country: China
facility: Taizhou Hospital of Zhejiang Province
city: Nantong
country: China
facility: Nantong Tumor Hospital
city: Shanghai
country: China
facility: Ruijin Hospital Shanghai Jiao Tong University
city: Shanghai
country: China
facility: Shanghai Chest Hospital
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
city: Shanghai
country: China
facility: Shanghai East Hospital
city: Shenyang
country: China
facility: Shengjing Hospital Of China Medical University
city: Tianjin
country: China
facility: Tianjin Medical University General Hospital
city: Urumchi
country: China
facility: Cancer Hospital of Xinjiang Medical University
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University
city: Wuhan
country: China
facility: TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
city: XI An
country: China
facility: The First Affiliated Hospital of Xian Jiaotong University
city: Yantai
country: China
facility: Yantai Yuhuangding Hospital
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
city: Bordeaux
country: France
facility: Institut Bergonie
city: Bron
country: France
facility: Hospices Civils de Lyon HCL
city: La Tronche
country: France
facility: CHU de Grenoble Hopital Albert Michallon
city: Lille
country: France
facility: Institute Coeur Poumon
city: Limoges
country: France
facility: CHU de Limoges
city: Marseille Cedex 20
country: France
facility: Hopital Nord
city: Paris
country: France
facility: Institut Curie
city: Paris
country: France
facility: Hopital Tenon
city: Pessac
country: France
facility: CHU Bordeaux
city: Sain-Herblain
country: France
facility: CHU Nantes
city: Saint Mande
country: France
facility: HIA Begin
city: Tours
country: France
facility: CHU Bretonneau
city: Villejuif Cedex
country: France
facility: Institut Gustave Roussy
city: Bad Berka
country: Germany
facility: Zentralklinik Bad Berka GmbH
city: Berlin
country: Germany
facility: Helios Klinikum Emil von Behring GmbH
city: Essen
country: Germany
facility: Universitaetsklinikum Essen
city: Gauting
country: Germany
facility: Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
city: Halle (Saale)
country: Germany
facility: Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
city: Heidelberg
country: Germany
facility: Thoraxklinik am Universitatsklinikum Heidelberg
city: Heilbronn
country: Germany
facility: Onkologische Schwerpunktpraxis
city: Koeln
country: Germany
facility: Kliniken der Stadt Koeln gGmbH
city: Leipzig
country: Germany
facility: POIS Leipzig GbR
city: Oldenburg
country: Germany
facility: Pius-Hospital Oldenburg
city: Stuttgart
country: Germany
facility: Robert-Bosch-Krankenhaus - Klinik Schillerhoehe
city: Budapest
country: Hungary
facility: Orszagos Koranyi Tbc es Pulmonologiai Intezet
city: Farkasgyepü
country: Hungary
facility: Veszprém Megyei Tudőgyógyintézet
city: Gyöngyös
country: Hungary
facility: Mátrai Gyógyintézet-Bronchológia
city: Szekesfehervar
country: Hungary
facility: Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
city: Szombathely
country: Hungary
facility: Markusovszky Egyetemi Oktatokorhaz
city: Torokbalint
country: Hungary
facility: Tudogyogyintezet Torokbalint
city: Hyderabad
country: India
facility: Basavatarakam Indo-American Hospital
city: Kolkata
country: India
facility: Tata Medical Center
city: Mumbai
country: India
facility: Tata Memorial Hospital
city: Nasik
country: India
facility: HCG Manavta Cancer Centre
city: Pune
country: India
facility: Noble Hospital Pvt Ltd
city: Haifa
country: Israel
facility: Rambam Health Corporation
city: Jerusalem
country: Israel
facility: Hadassah Medical Center
city: Kfar Saba
country: Israel
facility: Meir Medical Center
city: Petah Tikva
country: Israel
facility: Rabin Medical Center
city: Ramat Gan
country: Israel
facility: Chaim Sheba Medical Center
city: Tel-Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
city: Avellino
country: Italy
facility: Ospedale San Giuseppe Moscati di Avellino
city: Catania
country: Italy
facility: Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
city: Meldola
country: Italy
facility: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
city: Milano
country: Italy
facility: Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
city: Milano
country: Italy
facility: IRCCS Ospedale San Raffaele
city: Milano
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori
city: Milano
country: Italy
facility: Istituto Europeo di Oncologia
city: Monza
country: Italy
facility: San Gerardo Hospital
city: Napoli
country: Italy
facility: Ospedale Monaldi
city: Orbassano
country: Italy
facility: Aou San Luigi Gonzaga
city: Ravenna
country: Italy
facility: Ospedale S. Maria Delle Croci
city: Roma
country: Italy
facility: Irccs Gemelli
city: Rozzano
country: Italy
facility: Istituto Clinico Humanitas
city: Bunkyo Ku
country: Japan
facility: Juntendo University Hospital
city: Chuo Ku
country: Japan
facility: National Cancer Center Hospital
city: Fukuoka
country: Japan
facility: National Hospital Organization Kyushu Medical Center
city: Himeji
country: Japan
facility: National Hospital Organization Himeji Medical Center
city: Hirakata
country: Japan
facility: Kansai Medical University Hospital
city: Kanazawa
country: Japan
facility: Kanazawa University Hospital
city: Kashiwa
country: Japan
facility: National Cancer Center Hospital East
city: Kurume
country: Japan
facility: Kurume University Hospital
city: Matsusaka
country: Japan
facility: Matsusaka Municipal Hospital
city: Niigata
country: Japan
facility: Niigata Cancer Center Hospital
city: Okayama
country: Japan
facility: Okayama University Hospital
city: Osaka Sayama shi
country: Japan
facility: Kindai University Hospital
city: Shibukawa
country: Japan
facility: National Hospital Organization Shibukawa Medical Center
city: Tokyo
country: Japan
facility: The Cancer Institute Hospital of JFCR
city: Tokyo
country: Japan
facility: National Hospital Organization Tokyo Medical Center
city: Toon-shi
country: Japan
facility: Ehime University Hospital
city: Toyonaka-shi
country: Japan
facility: National Hospital Organization Osaka Toneyama Medical Center
city: Wakayama
country: Japan
facility: Wakayama Medical University Hospital
city: Yamaguchi
country: Japan
facility: National Hospital Organization Iwakuni Clinical Center
city: Yamaguchi
country: Japan
facility: National Hospital Organization Yamaguchi Ube Medical Center
city: Busan
country: Korea, Republic of
facility: Inje University Haeundae Paik Hospital
city: Cheongju-si
country: Korea, Republic of
facility: Chungbuk National University Hospital
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea Seoul St Mary s Hospital
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital
city: George Town
country: Malaysia
facility: Hospital Pulau Pinang
city: Johor Bahru
country: Malaysia
facility: Hospital Sultan Ismail
city: Kuala Lumpur
country: Malaysia
facility: Hospital Kuala Lumpur
city: Kuala Lumpur
country: Malaysia
facility: University Malaya Medical Centre
city: Kuantan
country: Malaysia
facility: Hospital Tengku Ampuan Afzan
city: Petaling Jaya
country: Malaysia
facility: Beacon Hospital Sdn Bhd
city: Ciudad de Mexico
country: Mexico
facility: Mexico Centre for Clinical Research, S.A. de C.V.
city: Ciudad de Mexico
country: Mexico
facility: Médica Sur
city: Guadalajara
country: Mexico
facility: Hospital Civil de Guadalajara Fray Antonio Alcalde
city: Leon
country: Mexico
facility: CIMOVA, Morals Vargas Centro de Investigación SC
city: Mexico
country: Mexico
facility: Health Pharma Professional Research
city: Mexico
country: Mexico
facility: Instituto Nacional de Cancerologia
city: Monterrey
country: Mexico
facility: i Can Oncology Center
city: Naucalpan
country: Mexico
facility: Oncologia Integral Satelite
city: Arnhem
country: Netherlands
facility: Rijnstate Ziekenhuis
city: Harderwijk
country: Netherlands
facility: Ziekenhuis St Jansdal
city: Nijmegen
country: Netherlands
facility: UMC Radboud
city: s-Hertogenbosch
country: Netherlands
facility: Jeroen Bosch Ziekenhuis
city: Bydgoszcz
country: Poland
facility: Centrum Onkologii im Prof F Lukaszczyka
city: Gdansk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne
city: Gdynia
country: Poland
facility: Szpitale Pomorskie Sp z o o
city: Olsztyn
country: Poland
facility: Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
city: Poznan
country: Poland
facility: Private Specialist Hospitals - MedPolonia
city: Warszawa
country: Poland
facility: Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
city: Lisboa
country: Portugal
facility: Uls Santa Maria - Hosp. Pulido Valente
city: Porto
country: Portugal
facility: Uls Santo Antonio - Hosp. Santo Antonio
city: Porto
country: Portugal
facility: Hosp. Cuf Porto
city: Porto
country: Portugal
facility: Instituto Portugues de Oncologia
city: Rio Piedras
country: Puerto Rico
facility: Pan American Center for Oncology Trials LLC
city: Irkutsk
country: Russian Federation
facility: Irkutsk Regional Oncology Dispensary
city: Krasnogorsk
country: Russian Federation
facility: Moscow City Oncology Hospital № 62
city: Krasnoyarsk
country: Russian Federation
facility: Krasnoyarsk Regional Oncology Dispensary
city: Kuzmolovsky
country: Russian Federation
facility: Leningrad Regional Oncology Dispensary
city: Moscow
country: Russian Federation
facility: MCK
city: Nalchik
country: Russian Federation
facility: City Clinical Hospital #1
city: Nizhniy Novgorod
country: Russian Federation
facility: Nizhny Novgorod Regional Oncological Dispensary
city: Omsk
country: Russian Federation
facility: Omsk Clinical Oncology Dispensary
city: Saint Petersburg
country: Russian Federation
facility: Current medical technologies
city: Saint Petersburg
country: Russian Federation
facility: N.N. Petrov Research Institute Of Oncology
city: St-Petersburg
country: Russian Federation
facility: Oncology Medical Clinics AV Medical group
city: Tambov
country: Russian Federation
facility: Tambov Regional Oncology Clinical Dispansary
city: Tomsk
country: Russian Federation
facility: Tomsk Cancer Research Institute
city: Ufa
country: Russian Federation
facility: Bashkir State Medical University
city: Yaroslavl
country: Russian Federation
facility: Yaroslavl Regional Clinical Oncology Hospital
city: A Coruna
country: Spain
facility: Hosp Univ A Coruna
city: Badalona
country: Spain
facility: Inst. Cat. D'Oncologia-Badalona
city: Barcelona
country: Spain
facility: Hosp. de La Santa Creu I Sant Pau
city: Barcelona
country: Spain
facility: Hosp. Univ. Quiron Dexeus
city: Barcelona
country: Spain
facility: Hosp Univ Vall D Hebron
city: Burgos
country: Spain
facility: Hosp. Univ. de Burgos
city: Girona
country: Spain
facility: Institut Català D'Oncologia Girona
city: Madrid
country: Spain
facility: Hosp. Gral. Univ. Gregorio Maranon
city: Madrid
country: Spain
facility: Hosp. Univ. 12 de Octubre
city: Madrid
country: Spain
facility: Hosp. Univ. La Paz
city: Majadahonda
country: Spain
facility: Hosp. Univ. Pta. de Hierro Majadahonda
city: Malaga
country: Spain
facility: Hosp Regional Univ de Malaga
city: Pamplona
country: Spain
facility: Clinica Univ. de Navarra
city: Seville
country: Spain
facility: Hosp. Virgen Del Rocio
city: Valencia
country: Spain
facility: Hosp. Gral. Univ. Valencia
city: Zaragoza
country: Spain
facility: Hosp. Clinico Univ. Lozano Blesa
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung Ho Memorial Hospital
city: Kaohsiung
country: Taiwan
facility: E-DA Hospital
city: Kaohsiung
country: Taiwan
facility: Chang Gung Medical Foundation
city: New Taipei
country: Taiwan
facility: Taipei Medical University Shuang Ho Hospital
city: Taichung
country: Taiwan
facility: Chung Shan Medical University Hospital
city: Taichung
country: Taiwan
facility: China Medical University Hospital
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei City
country: Taiwan
facility: National Taiwan University Hospital
city: Bangkok
country: Thailand
facility: Phramongkutklao Hospital and Medical College
city: Bangkok
country: Thailand
facility: Siriraj Hospital
city: Chiangmai
country: Thailand
facility: Chiang Mai University
city: Songkla
country: Thailand
facility: Songklanagarind Hospital, Prince of Songkla University
city: Adana
country: Turkey
facility: Adana City Hospital
city: Adana
country: Turkey
facility: Başkent University Medical Faculty Adana Application and Research Center
city: Ankara
country: Turkey
facility: Gazi University Hospital
city: Ankara
country: Turkey
facility: Ankara Bilkent City Hospital
city: Edirne
country: Turkey
facility: Trakya University Medical Faculty
city: Istanbul
country: Turkey
facility: Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
city: Istanbul
country: Turkey
facility: Medipol Mega University Hospital
city: Istanbul
country: Turkey
facility: T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
city: Izmir
country: Turkey
facility: Medical Point
city: Konya
country: Turkey
facility: Necmettin Erbakan University Meram Medical Faculty
city: Dnipro
country: Ukraine
facility: Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
city: Kharkiv
country: Ukraine
facility: Municipal non-profit enterprise 'Regional Center of Oncology'
city: Kyiv
country: Ukraine
facility: Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
city: Kyiv
country: Ukraine
facility: National Cancer Institute
city: Uzhgorod
country: Ukraine
facility: Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal
city: Edinburgh
country: United Kingdom
facility: Edinburgh Cancer Centre Western General
city: London
country: United Kingdom
facility: UCL Cancer Institute
city: London
country: United Kingdom
facility: Chelsea And Westminster Hospital
city: London
country: United Kingdom
facility: The Royal Marsden NHS Trust
city: Manchester
country: United Kingdom
facility: Christie NHS Foundation Trust
city: Nottingham
country: United Kingdom
facility: Nottingham University Hospitals NHS Trust
city: Sutton
country: United Kingdom
facility: The Royal Marsden NHS Trust
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC Clinical Trial
role: STUDY_DIRECTOR
References:
citation: Cho BC, Felip E, Hayashi H, Thomas M, Lu S, Besse B, Sun T, Martinez M, Sethi SN, Shreeve SM, Spira AI. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022 Feb;18(6):639-647. doi: 10.2217/fon-2021-0923. Epub 2021 Dec 16.